Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 8/20 | 0.47 |
| ▸ | BCR | P11274 | 2/20 | 0.47 |
| ▸ | PRKCA | P17252 | 2/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.45 |
| ▸ | RET | P07949 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3554974 | 0.89 | ALDH1A1 (0.48) | MAPK10ABL1ALDH1A1GAA | |
| SCHEMBL3562948 | 0.87 | CYP1A2 (0.47) | ABL1BCRPRKCAEGFRSRC | |
| SCHEMBL4262443 | 0.84 | ABL1 (0.55) | ABL1BCRPRKCAEGFRSRC | |
| SCHEMBL4264785 | 0.82 | KARS1 (0.54) | ABL1BCRPRKCAEGFRSRC | |
| SCHEMBL4266541 | 0.82 | ALDH1A1 (0.49) | ABL1BCRPRKCAEGFRSRC | |
| SCHEMBL4276994 | 0.82 | ALDH1A1 (0.48) | ABL1BCRPRKCAEGFRSRC | |
| SCHEMBL29364396 | 0.81 | ABL1 (0.69) | ABL1BCRPRKCAEGFRSRC | |
| SCHEMBL1550 | 0.81 | ABL1 (0.69) | ABL1BCRPRKCAEGFRSRC | |
| Water SCHEMBL28827802 | 0.81 | ABL1 (0.68) | ABL1BCRPRKCAEGFRSRC | |
| SCHEMBL2924553 | 0.80 | ABL1 (0.64) | MAPK10ABL1BCRPRKCARIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013035102-A1 | PROCESSES FOR THE PREPARATION OF IMATINIB BASE AND INTERMEDIATES THEREOF | NATCO PHARMA LIMITED (IN) | 2013-03-14 | — | — | WO | claimed |
| EP-1833815-B1 | A PROCESS FOR PREPARATION OF IMATINIB BASE | INST FARMACEUTYCZNY (PL) | 2010-09-15 | — | — | EP | claimed |
| US-20080194819-A1 | Process For Preparation of Imatinib Base | INSTYTUT FARMACEUTYCZNY (PL) | 2008-08-14 | — | — | US | claimed |
| EP-1833815-A2 | A PROCESS FOR PREPARATION OF IMATINIB BASE | INSTYTUT FARMACEUTYCZNY (PL) | 2007-09-19 | — | — | EP | claimed |
| WO-2006071130-A2 | A PROCESS FOR PREPARATION OF IMATINIB BASE | INSTYTUT FARMACEUTYCZNY (PL) | 2006-07-06 | — | — | WO | claimed |
| EP-3299358-A1 | AMIDE DERIVATIVE AND MEDICINE | Nippon Shinyaku Co., Ltd. (JP) | 2018-03-28 | — | — | EP | disclosed |
| EP-1702917-B1 | AMIDE DERIVATIVE AND MEDICINE | NIPPON SHINYAKU CO LTD (JP) | 2017-08-02 | — | — | EP | disclosed |
| US-9095622-B2 | Oligomer-protein tyrosine kinase inhibitor conjugates | NEKTAR THERAPEUTICS (US) | 2015-08-04 | — | — | US | disclosed |
| US-20150073006-A1 | OLIGOMER-PROTEIN TYROSINE KINASE INHIBITOR CONJUGATES | NEKTAR THERAPEUTICS | 2015-03-12 | — | — | US | disclosed |
| US-8921371-B2 | Oligomer-protein tyrosine kinase inhibitor conjugates | NEKTAR THERAPEUTICS (US) | 2014-12-30 | — | — | US | disclosed |
| US-20140080839-A1 | OLIGOMER-PROTEIN TYROSINE KINASE INHIBITOR CONJUGATES | NEKTAR THERAPEUTICS (US) | 2014-03-20 | — | — | US | disclosed |
| US-8530492-B2 | Oligomer-protein tyrosine kinase inhibitor conjugates | NEKTAR THERAPEUTICS (US) | 2013-09-10 | — | — | US | disclosed |
| US-7494997-B2 | Amide derivative | NIPPON SHINYAKU CO., LTD. (JP) | 2009-02-24 | — | — | US | disclosed |
| US-20080293940-A1 | Amide Derivative and Medicine | NIPPON SHINYAKU CO., LTD. (JP) | 2008-11-27 | — | — | US | disclosed |
| US-20080194819-A1 | Process For Preparation of Imatinib Base | INSTYTUT FARMACEUTYCZNY (PL) | 2008-08-14 | — | — | US | disclosed |
| EP-1833815-A2 | A PROCESS FOR PREPARATION OF IMATINIB BASE | INSTYTUT FARMACEUTYCZNY (PL) | 2007-09-19 | — | — | EP | disclosed |
| EP-1702917-A1 | AMIDE DERIVATIVE AND MEDICINE | Nippon Shinyaku Co., Ltd. (JP) | 2006-09-20 | — | — | EP | disclosed |
| WO-2006071130-A2 | A PROCESS FOR PREPARATION OF IMATINIB BASE | INSTYTUT FARMACEUTYCZNY (PL) | 2006-07-06 | — | — | WO | disclosed |
| US-20060014742-A1 | Amide derivative | NIPPON SHINYAKU CO., LTD. (JP) | 2006-01-19 | — | — | US | disclosed |
| EP-1533304-A1 | AMIDE DERIVATIVE | Nippon Shinyaku Co., Ltd. (JP) | 2005-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014742-A1 | Amide derivative | ABL1, ABL2, BCR | MAPK10 441/4885ABL1 1/4885BCR 3/4885 |
| US-20080194819-A1 | Process For Preparation of Imatinib Base | ABL1, ABL2, JAK2 | MAPK10 734/4885ABL1 1/4885BCR 12/4885 |
| US-20150073006-A1 | OLIGOMER-PROTEIN TYROSINE KINASE INHIBITOR CONJUGATES | PTK2B, ERBB2, FRK | MAPK10 372/4885ABL1 30/4885BCR 323/4885 |
| US-20140080839-A1 | OLIGOMER-PROTEIN TYROSINE KINASE INHIBITOR CONJUGATES | PTK2B, ERBB2, FRK | MAPK10 372/4885ABL1 30/4885BCR 323/4885 |
| US-20080293940-A1 | Amide Derivative and Medicine | ABL2, ABL1, BCR | MAPK10 453/4885ABL1 2/4885BCR 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.